satsuma pharmaceuticals grabs m series a    your source for venture capital and private equity financings    massinvestorvc news daily           vc directories mobile apps celebrity vcs venturetrackr archive about us   satsuma pharmaceuticals grabs m series a  tweet         san francisco ca leader in developing bestinclass therapies to address the unmet needs of migraine sufferers today announced the closing of a  million series a financing click here for more funding data on satsuma to export satsuma funding data to pdf and excel click here satsuma pharmaceuticals inc a leader in developing bestinclass therapies to address the unmet needs of migraine sufferers today announced the closing of a  million series a financing coled by ra capital management and tpg biotech ra capital portfolio manager and managing director rajeev shah and tpg biotech partner and managing director heath lukatch phd have joined satsumas board of directorssatsuma pharmaceuticals plans to utilize funds provided by the series a financing to accelerate development of its lead product candidate sts sts is a potential bestinclass therapy for migraine that combines the goldstandard antimigraine drug dihydroergotamine dhe with unique and proprietary drypowder nasal formulation and delivery technologies created and developed over the past  years by snbl that enable rapid absorption with high bioavailability of drugs delivered via the nose dhe has multiple therapeutic advantages over other migraine therapies including triptan therapies but is not currently available in a fastacting patientfriendly noninjectable preparation that achieves a pharmacokinetic profile similar to that achieved with injection sts has undergone extensive preclinical optimization and evaluation based on pharmacokinetic data generated to date satsuma anticipates sts will have a rapid onset of action and be highly effective and welltolerated in a large number of migraine sufferers whose needs are not well served with current therapies including those with difficulttotreat migraine types we look forward to building upon the strong technology foundation established by our colleagues at snbl over the past  years expeditiously advancing development of sts and making sts available to migraine sufferers commented john kollins satsuma pharmaceuticals cofounder president and chief executive officer many migraine sufferers are underserved with current therapies and we believe the market for migraine therapeutics is poised for significant growth commented rajeev shah portfolio manager and managing director at ra capital we believe satsuma pharmaceuticals and sts are wellpositioned to deliver meaningful clinical benefits to patients with a highlydifferentiated bestinclass product that will be a valued addition to physicians antimigraine armamentarium our diligence indicates physicians and migraine sufferers strongly desire a fastacting effective noninjected dhe product with the profile and attributes we anticipate sts will have we look forward to working with satsuma and snbl to support development of sts and potentially additional products that utilize snbls unique drypowder nasal formulation and delivery technology to address significant unmet patient needs said heath lukatch phd partner and managing director at tpg biotechabout shin nippon biomedical laboratories ltdheadquartered in tokyo japan snbl is a leading global preclinical and clinical contract research services provider and creator of innovative therapeutic technologies including the proprietary drypowder nasal formulation and drug delivery device technologies incorporated in satsumas lead product candidate sts and the stereopure nucleic acid therapeutic technology being developed by snbl spinout company wave life sciences nasdaq wvefor additional information please visit httpwwwsnblcojpabout ra capital management ra capital management is a crossover investment manager dedicated to evidencebased investing in public and private healthcare and life science companies that are developing drugs medical devices and diagnostics the flexibility of its strategy allows ra capital to lead private ipo and followon financings for its portfolio companies both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercializationabout tpg biotechtpg biotech is tpgs life science venture capital platform with  billion in assets under management tpg biotech focuses on subsectors such as therapeutics medical devices and healthcare services tpgs team which includes experienced investors physicians scientists and technical experts partners with innovative companies and talented entrepreneurs to expand and create new businesses since  tpg biotech has invested in more than  life science businesses c by massinvestor inc for contact info please check out our about page    click here for indepth research on  vc firms   massinvestorvc news daily  massinvestor inc vc directories mobile apps celebrity vcs venturetrackr archive funded companies about us satsuma pharmaceuticals inc  california company directory « » az list  a b c d e f g h i j k l m n o p q r s t u v w x y z  satsuma pharmaceuticals inc satsuma pharmaceuticals inc was incorporated on  this company is now active their business is recorded as foreign stock as so far this company has running for  years  days company details company number c9 name satsuma pharmaceuticals inc incorporation date  type foreign stock active status active registered office address  third ave san francisco ca  9 last statement filed on  agent for service of process c t corporation system  w th st ste 9 los angeles ca  9 information updated   added   similar satsuma villas homeowners association satsuma farms inc satsuma street inc satsuma village homeowners association satsuma artist condos owners association satsuma townhomes homeowners association pharmaceuticals plus usa inc cell surgical network international inc the chariot traveler inc the trainor team inc the existence inc jc trending dsuccess marketing inc cth skin corp neighborhoodlifelineorg shelbys safespace malted capital inc satsuma pharmaceuticals inc mistral hunter restaurant wards auto supply inc deep connection technologies inc tripplus travel service inc navloan inc kertac inc data disclaimer the information provided on cacompanyorg is all collected from official company registers and other public data sources all the data are provided as a guideline and have been prepared only for information purposes only we try to keep this information correct and uptodate but it is not the primary source and the company registry should always be referred to for definitive information therefore we cannot make any promises as to the quality of company data you use the company data entirely at your own risk microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext9 personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft satsuma pharmaceuticals  cb insights × name your new list come up with a name for your new list and well add to it cancel create list customers case studies  testimonials all  testimonials deal makers venture capital corporate development  ma corporate venture capital sales  business development investment banks wealth management growth equity investors strategy  product corporate strategy corporate innovation competitive intelligence strategy consulting product development advisors  consulting investment banks lawyers strategy consulting nonprofits universities economic development platform venture capital database insights  company intel business social graph mosaic rating company mosaic investor mosaic market mosaic analytics  data viz industry analytics investor analytics geo analytics venture capital and maipo data deal feeds  alerts productivity tools chrome browser plugin mobile app services ondemand research custom content  marketing services expert by cb insights research get our newsletter k have it reports webinars research blog insurance tech blog the company about us press were hiring team blog pricing try us for free log in login try us for free customers case studies  testimonials read all  testimonials deal makers venture capital firms corporate venture corporate development  ma growth equity investors investment banks wealth management advisors  consulting law firms strategy consulting strategy  product strategy consulting corporate strategy corporate innovation competitive intelligence product development sales and business development nonprofits universities economic development organizations platform insights  company intel business social graph mosaic rating company mosaic investor mosaic market mosaic venture capital and maipo data venture capital database private company valuations  multiples analytics  data viz industry analytics investor analytics geo analytics productivity tools chrome browser plugin mobile app services ondemand research custom content  marketing services expert by cb insights research get our newsletter k have it reports webinars research blog insurance tech blog the company about us press were hiring team blog pricing already a member click here to login   close satsuma pharmaceuticals satsumarxcom download pdf follow public lists dashboard performance jobs financing board competitors patents satsuma pharmaceuticals develops bestinclass therapies to address the unmet needs of migraine sufferers the companys lead product candidate sts is a potential bestinclass therapy for migraine that combines the goldstandard antimigraine drug dihydroergotamine dhe with unique and proprietary drypowder nasal formulation and delivery technologies created and developed over the past  years by snbl that enable rapid absorption with high bioavailability of drugs delivered via the noseshow all satsuma pharmaceuticals develops bestinclass therapies to address the unmet needs of migraine sufferers the companys lead product candidate sts is a potential bestinclass therapy for migraine that combines the goldstandard antimigraine drushow all company alive  active all investors data  investors ra capital managementtpg biotech phone  fax  rd avenue suite  south san francisco 9 california united states latest news see all  articles see more competitors data competitors total funding date of last funding satsuma pharmaceuticals m dec   see all  competitors web traffic rank show  engagement pvpu show  domain authority score show page views per million pvpm show reach per million show rank page views per user pvpu page views per million pvpm reach per million rpm w m m y w m m y w m m y w m m y seo statistics domain authority score show page authority score show no external links show no links show web traffic statistics  growth per week per month per  months per year rank login to see details page views per million login to see details page views per user login to see details reach per million login to see details related satsuma pharmaceuticals jobs jobs by there is no financing data available for this company please select another tab investors investor investor type location participating rounds see all  investors there is no board of directors data available for this company please select another tab board members name firm login to see detailstpg biotechlogin to see detailsra capital management there is no competitors data available for this company please select another tab competitors company status description investors see all  competitors patents title application date patent date status patent  application satsuma pharmaceuticals  developing bestinclass migraine therapies satsuma pharmaceuticals  developing bestinclass migraine therapies satsuma pharmaceuticals spins out from shin nippon biomedical laboratories snbl with funding from satsuma pharmaceuticals spins out from shin nippon biomedical laboratories snbl with funding from leading institutional life science investors   million series a financing supports development of bestinclass therapy for acute migraine that incorporates novel and proprietary snbl nasal drug delivery technology  news provided by satsuma pharmaceuticals inc jan    et share this article san francisco jan   prnewswire  satsuma pharmaceuticals inc a leader in developing bestinclass therapies to address the unmet needs of migraine sufferers today announced the closing of a  million series a financing coled by ra capital management and tpg biotech  ra capital portfolio manager and managing director rajeev shah and tpg biotech partner and managing director heath lukatch phd have joined satsumas board of directors satsuma pharmaceuticals plans to utilize funds provided by the series a financing to accelerate development of its lead product candidate sts  sts is a potential bestinclass therapy for migraine that combines the goldstandard antimigraine drug dihydroergotamine dhe with unique and proprietary drypowder nasal formulation and delivery technologies created and developed over the past  years by snbl that enable rapid absorption with high bioavailability of drugs delivered via the nose  dhe has multiple therapeutic advantages over other migraine therapies including triptan therapies but is not currently available in a fastacting patientfriendly noninjectable preparation that achieves a pharmacokinetic profile similar to that achieved with injection  sts has undergone extensive preclinical optimization and evaluation based on pharmacokinetic data generated to date satsuma anticipates sts will have a rapid onset of action and be highly effective and welltolerated in a large number of migraine sufferers whose needs are not well served with current therapies including those with difficulttotreat migraine types we look forward to building upon the strong technology foundation established by our colleagues at snbl over the past  years expeditiously advancing development of sts and making sts available to migraine sufferers commented john kollins satsuma pharmaceuticals cofounder president and chief executive officer  many migraine sufferers are underserved with current therapies and we believe the market for migraine therapeutics is poised for significant growth commented rajeev shah portfolio manager and managing director at ra capital we believe satsuma pharmaceuticals and sts are wellpositioned to deliver meaningful clinical benefits to patients with a highlydifferentiated bestinclass product that will be a valued addition to physicians antimigraine armamentarium  our diligence indicates physicians and migraine sufferers strongly desire a fastacting effective noninjected dhe product with the profile and attributes we anticipate sts will have  we look forward to working with satsuma and snbl to support development of sts and potentially additional products that utilize snbls unique drypowder nasal formulation and delivery technology to address significant unmet patient needs said heath lukatch phd partner and managing director at tpg biotech about shin nippon biomedical laboratories ltdheadquartered in tokyo japan snbl is a leading global preclinical and clinical contract research services provider and creator of innovative therapeutic technologies including the proprietary drypowder nasal formulation and drug delivery device technologies incorporated in satsumas lead product candidate sts and the stereopure nucleic acid therapeutic technology being developed by snbl spinout company wave life sciences nasdaq wve for additional information please visit httpwwwsnblcojp about ra capital management ra capital management is a crossover investment manager dedicated to evidencebased investing in public and private healthcare and life science companies that are developing drugs medical devices and diagnostics the flexibility of its strategy allows ra capital to lead private ipo and followon financings for its portfolio companies both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization about tpg biotechtpg biotech is tpgs life science venture capital platform with  billion in assets under management tpg biotech focuses on subsectors such as therapeutics medical devices and healthcare services tpgs team which includes experienced investors physicians scientists and technical experts partners with innovative companies and talented entrepreneurs to expand and create new businesses  since  tpg biotech has invested in more than  life science businesses corporate contact         john kollins president  chief executive officersatsuma pharmaceuticals incjohnsatsumarxcom for additional information please visit satsuma pharmaceuticals website wwwsatsumarxcom   to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasessatsumapharmaceuticalsspinsoutfromshinnipponbiomedicallaboratoriessnblwithfundingfromleadinginstitutionallifescienceinvestorshtml source satsuma pharmaceuticals inc related links httpwwwsatsumarxcom my news release contains wide tables view fullscreen you just read satsuma pharmaceuticals spins out from shin nippon biomedical laboratories snbl with funding from leading institutional life science investors news provided by satsuma pharmaceuticals inc jan    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search satsuma pharmaceuticals inc  company profile  biocentury publications archives bciq conferences version  free trial  subscribe sign in english   한국어 biocentury menu home  publications  publications home  biocentury bc innovations bc extra bc week in review current issues archives  archives home  basic search advanced search back issues bciq  bciq home  overview pipeline analyst financial analyst company analyst deal analyst conferences  conferences home  newsmakers bio€quity europe future leaders china healthcare summit other industry events elearning  elearning home  videos white papers follow us bciq  company profile bciq overview      settings      support biocentury print this       satsuma pharmaceuticals inc print preview export bookmark share with colleague general information  location south san francisco calif  region san francisco bay area  country us  business category neurology  year founded   website httpwwwsatsumarxcom  lead product status preclinical  archive items are loading  financial information  financing summary  financing details  earnings summary  stocks annual chart  pipeline information  pipeline summary  pipeline details  deals information  deals summary  deals details about biocentury company overview management editorial  research contact contact us advertising  sponsorship career opportunities support forgot password customer service reprints faqs products  solutions products overview publications archives bciq conferences elearning rss feeds legal user agreement terms of use privacy policy your california privacy rights use of images follow us what is biocentury biocentury employs a fully integrated multimedia platform — including publications video online data solutions and conferences — to provide its audience with authoritative and uptodate intelligence about corporate strategy partnering emerging technology clinical data public policy and the financial markets sign in free trial   biocentury inc all rights reserved    terms  conditions  privacy policy set email alert dummy satsuma pharmaceuticals takes in  mln series a  pe hub subscribe to pe hub wire join over  of your peers get the mustread email for pevc professionals delivered to your inbox daily — for free us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions subscribe yes no registersign in a community for professionals in private capital satsuma pharmaceuticals takes in  mln series a january   by iris dorbian print email share via email separate multiple email addresses with commas share send me a copy email preview to from subject look at this story on pe hub satsuma pharmaceuticals takes in  mln series a satsuma pharmaceuticals inc which is focused on treating migraines has raised  million series in a financing ra capital management and tpg biotech led the round in conjunction with the funding rajeev shah ra capital portfolio manager and managing director and dr heath lukatch tpg biotech partner and managing director have been added to satsumas board of directors continue reading on pe hub writes satsuma pharmaceuticals inc which is focused on treating migraines has raised  million series in a financing ra capital management and tpg biotech led the round in conjunction with the funding rajeev shah ra capital portfolio manager and managing director and dr heath lukatch tpg biotech partner and managing director have been added to satsuma’s board of directors source press release print email share via email separate multiple email addresses with commas share send me a copy email preview to from subject look at this story on pe hub satsuma pharmaceuticals takes in  mln series a satsuma pharmaceuticals inc which is focused on treating migraines has raised  million series in a financing ra capital management and tpg biotech led the round in conjunction with the funding rajeev shah ra capital portfolio manager and managing director and dr heath lukatch tpg biotech partner and managing director have been added to satsumas board of directors continue reading on pe hub writes find new deal opportunities supercharge your fundraising efforts and track top managers with vcj get your free trial or subscribe now sign up to our newsletter receive updates from our pe hub wire and top stories of the week newsletters first name last name email address us edition daily canada edition weekly we will not send you spam and we dont share your email address with rd parties i accept the terms and conditions you are now subscribed to the pehub wire and top stories of the week newsletters buyouts insiderargosy group llc produces several free newsletters that are sent directly to the email you provide at registration namely pe hub wire pe hub canada wire pe hub wire top story of the week buyouts daily and vcj alert to enable us to keep providing these services free of charge we reserve the right to contact you with special invitations to sample or purchase private equityrelated products by submitting this free subscription request for any of these products you are also consenting to this communication should you ever wish to unsubscribe from a particular communication you may activate the unsubscribe mechanism at the bottom of the email this will discontinue both the special invitations mentioned previously as well as your subscription to the weekly newsletter the information you provide will be safeguarded by argosy group llcbuyouts insider the company’s subsidiaries may use it to keep you informed of relevant products and services we occasionally allow reputable companies outside of the company to mail details of products which may be of interest to you as an international group we may transfer your data on a global basis for the purposes indicated above we will never share your email or contact details with any outside company however should you have any questions please do not hesitate to contact us email protected top posts new oil and gas company native racks up  mln by iris dorbian kkr to buy nature’s bounty from carlyle by luisa beltran blackrock leads funding round for fintech platform icapital by iris dorbian platinum equity to buy united site services by luisa beltran the pe hub podcast episode two by staff report private equity jobs of the week priceline kpmg novaquest are hiring by eamon murphy the carveout curveball by pehublogger network raymond james expands team with new hire by iris dorbian satsuma pharmaceuticals spins out from shin nippon biomedical laboratories snbl with funding from leading institutional life science investorshomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets close in  hr 9 minssp 9 dow  nasdaq todays chartsdont get blindsided by teslas shiny new model satsuma pharmaceuticals spins out from shin nippon biomedical laboratories snbl with funding from leading institutional life science investorspr newswirejanuary  reblogsharetweetsharesan francisco jan   prnewswire  satsuma pharmaceuticals inc a leader in developing bestinclass therapies to address the unmet needs of migraine sufferers today announced the closing of a  million series a financing coled by ra capital management and tpg biotech  ra capital portfolio manager and managing director rajeev shah and tpg biotech partner and managing director heath lukatch phd have joined satsumas board of directorssatsuma pharmaceuticals plans to utilize funds provided by the series a financing to accelerate development of its lead product candidate sts  sts is a potential bestinclass therapy for migraine that combines the goldstandard antimigraine drug dihydroergotamine dhe with unique and proprietary drypowder nasal formulation and delivery technologies created and developed over the past  years by snbl that enable rapid absorption with high bioavailability of drugs delivered via the nose  dhe has multiple therapeutic advantages over other migraine therapies including triptan therapies but is not currently available in a fastacting patientfriendly noninjectable preparation that achieves a pharmacokinetic profile similar to that achieved with injection sts has undergone extensive preclinical optimization and evaluation based on pharmacokinetic data generated to date satsuma anticipates sts will have a rapid onset of action and be highly effective and welltolerated in a large number of migraine sufferers whose needs are not well served with current therapies including those with difficulttotreat migraine types we look forward to building upon the strong technology foundation established by our colleagues at snbl over the past  years expeditiously advancing development of sts and making sts available to migraine sufferers commented john kollins satsuma pharmaceuticals cofounder president and chief executive officer many migraine sufferers are underserved with current therapies and we believe the market for migraine therapeutics is poised for significant growth commented rajeev shah portfolio manager and managing director at ra capital we believe satsuma pharmaceuticals and sts are wellpositioned to deliver meaningful clinical benefits to patients with a highlydifferentiated bestinclass product that will be a valued addition to physicians antimigraine armamentarium our diligence indicates physicians and migraine sufferers strongly desire a fastacting effective noninjected dhe product with the profile and attributes we anticipate sts will have  we look forward to working with satsuma and snbl to support development of sts and potentially additional products that utilize snbls unique drypowder nasal formulation and delivery technology to address significant unmet patient needs said heath lukatch phd partner and managing director at tpg biotechabout shin nippon biomedical laboratories ltd headquartered in tokyo japan snbl is a leading global preclinical and clinical contract research services provider and creator of innovative therapeutic technologies including the proprietary drypowder nasal formulation and drug delivery device technologies incorporated in satsumas lead product candidate sts and the stereopure nucleic acid therapeutic technology being developed by snbl spinout company wave life sciences wvefor additional information please visit httpwwwsnblcojpabout ra capital management ra capital management is a crossover investment manager dedicated to evidencebased investing in public and private healthcare and life science companies that are developing drugs medical devices and diagnostics the flexibility of its strategy allows ra capital to lead private ipo and followon financings for its portfolio companies both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercializationabout tpg biotech tpg biotech is tpgs life science venture capital platform with  billion in assets under management tpg biotech focuses on subsectors such as therapeutics medical devices and healthcare services tpgs team which includes experienced investors physicians scientists and technical experts partners with innovative companies and talented entrepreneurs to expand and create new businesses  since  tpg biotech has invested in more than  life science businessesread morecorporate contact         john kollins president  chief executive officer satsuma pharmaceuticals inc johnsatsumarxcom for additional information please visit satsuma pharmaceuticals website wwwsatsumarxcom to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasessatsumapharmaceuticalsspinsoutfromshinnipponbiomedicallaboratoriessnblwithfundingfromleadinginstitutionallifescienceinvestorshtmlreblogsharetweetsharerecently viewedyour list is emptywhat to read nextwind projects in peril as indian states rethink purchasesbloombergthis will be in everyones household by banyan hillsponsoredamazon surpasses b mark bezos briefly becomes the world’s richest personinvestopediawework raised  million to expand in chinabusiness insider uklook for tweets and facebook posts in peltzs procter  gamble battle over retail votesthe streetengineer finds pattern makes millions in stocksmoney morningsponsoredmy next car is electrified says shell ceoautoblogthe two pizza rule is a secret to productive meetings that helped amazon ceo jeff bezos become one of the worlds richest menbusiness insiderthe real reason overseas manufacturing is coming to americayahoo financepeople in heavy debt may be in for a big surprisefreedom debt reliefsponsoredtax cuts just got more likelyyahoo financesbux unicorn frap wasn’t magical enough to save earningsyahoo finance videohow a oneofakind business has kept  kitchens out of landfillsyahoo financediscover it  out of  avg by k customersdiscover cardsponsoredtodays charts dont get blindsided by teslas shiny new model yahoo financetrump’s unwitting legacy could be universal health coverageyahoo financejeff sessions shouldn’t resign he should force trump to fire himtruthbetold trump has reduced the stature of all cabinet posts to a very sad statejoin the conversation